|
|
|
|
Science Sparks @ ACTREC
|
 18th November 2024 |
Vol. No. 13 ; Issue No.656 |
|
|
Publications
|
|
1. Goyal P, Kumar M, Kiran M, Srivastava S, Roy S, Garg S, Salunke S, Lader S, Quadir K, Ansari A, Fatima Z, Qayyumi B, Tuljapurkar V, Chaturvedi P (2024). Optimizing Surgical Margins in Oral Cancer without Frozen Section: A single center retrospective study. European Journal of Surgical Oncology.
2. Puranik AD, Dev ID, Rangarajan V, Jain Y, Patra S, Purandare NC, Sahu A, Choudhary A, Bhattacharya K, Gupta T, Chatterjee A, Dasgupta A, Moiyadi A, Shetty P, Singh V, Sridhar E, Sahay A, Shah A, Menon N, Ghosh S, Choudhury S, Shah S, Agrawal A, Lakshminarayanan N, Kumar A, Gopalakrishna A (2024). FET PET to differentiate between post-treatment changes and recurrence in high-grade gliomas: a single center multidisciplinary clinic controlled study. Neuroradiology.
Thesis
Bhawna Singh. 2024. Elucidating the role of BCCIP in cancer pathogenesis and development of resistance. (LIFE09201804008) (Guide: Dr. Shilpee Dutt)
|
|
|
|
|
Interesting Reads
|
|
Zhang S, Huang F, Wang Y, Long Y, Li Y, Kang Y, Gao W, Zhang X, Wen Y, Wang Y, Pan L, Xia Y, Yang Z, Yang Y, Mo H, Li B, Hu J, Song Y, Zhang S, Dong S, Du X, Li Y, Liu Y, Liao W, Gao Y, Zhang Y, Chen H, Liang Y, Chen J, Weng H, Huang H (2024). NAT10-mediated mRNA N4-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia. Nature Cell Biology.
|
|
|
Video of the Week
|
|
| Building Knowledge on childhood cancer through collaboration of cancer registries |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 1958, scientist developed 5-fluorouracil (5-FU), a chemotherapy drug used to treat many cancers. It is a first-line treatment for colon cancer.
|
|
|
|
Cancer News
|
| |
|
Researchers uncover new role of mutant RAS proteins in some of the deadliest cancers.
|
|
National Cancer Institute, 11/11/2024
|
|
In experiments in human lung cancer cell lines and mouse models of lung cancer, the researchers found that combining RAS inhibitors with different targeted cancer drugs that reactivate DLC1’s tumor suppressor activity had potent activity against cancer more potent than that of RAS inhibitors alone...
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
2024 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
